Type 2 Diabetes

A group of researchers is planning an ambitious project that could have implications for diseases like diabetes: to build a complete model of the pancreatic ß cell.

An analysis of 40-plus trials report that the closed loop system care can be the difference in 2.5 extra hours of daily normoglycemia.

The disparity of fast food swamps significantly affecting pediatric patients with T1D but not those with T2D came as a surprise to researchers.

SGLT-2 inhibitors and GLP-1 agonists were associated with 1% and 0.6% reductions in all-cause mortality, respectively.

In a new study, the GLP-1 receptor agonist semaglutide was associated with greater weight loss than placebo -- and liraglutide.

The benefit for patients without diabetes was +0.3 ml/min/1.73 m2 per year and for those with concurrent diabetes, the benefit was doubled to +.06 ml/min/1.73 m2.

Results indicated that canagliflozin provided renal benefits for T2D patients with preserved or reduced kidney function.

While conventional methods require some type of skin prick, scientists from the University of Bath have proven the concept of needleless CGM.

New data has elucidated a mechanism of action by which hormonal replacement therapy could help prevent T2D in women after menopause.

Phase 2 Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Commences.

Researchers note that efforts are needed to align clinical practice with clinical guidelines.

Three new diabetic technologies have been approved by the FDA. What are they? Scroll through our slideshow to find out. 

Study results showed significant HbA1c reduction when Bydureon was added to insulin glargine therapy versus insulin glargine alone.

A patch that can detect early symptoms of hypoglycemia is one of three studies discussed in this month's endocrinology news roundup.

The Beyond Type 1 Science Advisory Council member explains the warning signs of diabetes.

The device is the first of its class and will be designated as a class II device, subjecting it to special controls that will serve as criteria for future devices.

The Max SoloStar from Sanofi is capable of carrying 300 units/mL of insulin glargine, and administer 160 units/mL in a single injection.

It was announced this morning that dasiglucagon has met its primary and key secondary objectives in its multinational Phase 3 clinical trial in patients with severe hypoglycemia.

From degludec to dulaglutide, we’ve come a long way from the years when there was only one option to treat type 2 diabetes. Here's a look at metformin's place in this history.

Fasting sounds like a bad idea for anyone with type 2 diabetes and especially bad for someone taking antihyperglycemic drugs. But, is it really?

The device will offer real-time tracking and alerts for glucose level high and low events, as well as telemedicine capabilities.

A joint statement from the Endocrine Society, the ADA, the AACE, and the AADE expressed strong disagreement with the ACP’s new guidelines, which raised goal A1C levels to between 7% and 8% for patients with T2D.

The ability to monitor glucose levels quite literally with the blink of an eye has gotten one step closer to clinical application. Get a quick review.

The influenza virus can be debilitating for your diabetes patients for many reasons. Here are some tips to help you help them stay safe this year.